Related Experiment Video
Updated: Jan 2, 2026

06:15
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
1.7K
Hydroxyurea-induced cutaneous squamous cell carcinoma: A case report
1Department of Surgical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China.
World Journal of Clinical Cases
|December 14, 2019
Summary
Hydroxyurea (HU) therapy can cause severe skin issues, including squamous cell carcinoma. Early dermatologic monitoring is crucial for patients on long-term HU treatment to manage these cutaneous complications effectively.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Hydroxyurea (HU) is an S-phase specific antineoplastic agent inhibiting ribonucleoside reductase.
- It is widely used for leukemia, sickle cell anemia, psoriasis, and myeloproliferative disorders.
- Long-term HU therapy is associated with various cutaneous complications.

